Hanmi and Dongkook Lead Ibuprofen Cold Medicine Market; Chong Kun Dang and Dong‑A Join Competition This Fall

Last winter, Hanmi Pharmaceutical and Dongkook Pharmaceutical entered the ibuprofen‑combination cold‑medicine market. According to industry sources, the market competition is expected to intensify this autumn with the participation of Chong Kun Dang and Dong‑A Pharmaceutical. The shift follows the change in the standard manufacturing criteria for over‑the‑counter (OTC) products that took effect in January 2025. Although many companies have obtained product approvals since the change, only Hanmi (late last year) and Dongkook (early this year) have actually launched products so far. Because the market is still in its early formation stage and the peak cold‑medicine season has already begun, a full competitive landscape has not yet emerged.